1. Academic Validation
  2. Novel Quinazoline Derivatives Inhibit Splicing of Fungal Group II Introns

Novel Quinazoline Derivatives Inhibit Splicing of Fungal Group II Introns

  • ACS Chem Biol. 2025 Feb 21;20(2):378-385. doi: 10.1021/acschembio.4c00631.
Olga Fedorova 1 2 Michelle Luo 3 G Erik Jagdmann Jr 4 Michael C Van Zandt 4 Luke Sisto 2 Anna Marie Pyle 1 2 3
Affiliations

Affiliations

  • 1 Howard Hughes Medical Institute, Chevy Chase, Maryland 20815, United States.
  • 2 Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut 06520, United States.
  • 3 Department of Chemistry, Yale University, New Haven, Connecticut 06520, United States.
  • 4 New England Discovery Partners, Branford, Connecticut 06405, United States.
Abstract

We report the discovery of small molecules that target the RNA tertiary structure of self-splicing group II introns and display potent Antifungal activity against yeasts, including the major public health threat Candida parapsilosis. High-throughput screening efforts against a yeast group II intron resulted in an inhibitor class which was then synthetically optimized for enhanced inhibitory activity and Antifungal efficacy. The most highly refined compounds in this series display strong, gene-specific Antifungal activity against C. parapsilosis. This work demonstrates the utility of combining advanced RNA screening methodologies with medicinal chemistry pipelines to identify high-affinity ligands targeting RNA tertiary structures with important roles in human health and disease.

Figures
Products